Aurobindo Pharma Q1 net may rise 176% at Rs 137.5 cr: Emkay
Emkay Equity Advisory expects Aurobindo Pharma to report a 25.5 percent growth quarter-on-quarter (rise of 175.6 percent year-on-year) in net profit at Rs 137.5 crore.
August 08, 2013 / 19:49 IST
Emkay Equity Advisory has come out with its first quarter (April-June) earnings estimates for the pharmaceutical sector. The brokerage house expects Aurobindo Pharma to report a 25.5 percent growth quarter-on-quarter (rise of 175.6 percent year-on-year) in net profit at Rs 137.5 crore.
Revenues are expected to decrease by 3.5 percent Q-o-Q (up 24.8 percent Y-o-Y) to Rs 1,515.1 crore, according to Emkay Equity Advisory.Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 9.8 percent Q-o-Q (up 88.7 percent Y-o-Y) to Rs 263.6 crore.EBITDA margin or operating profit margin is likely to be at 17.4 percent in June quarter as against 15.3 percent in March quarter and 11.5 percent in a year ago period.Emkay Equity Advisory report on Aurobindo PharmaAurobindo should see a healthy quarter with solid growth across most segments also aided by some currency depreciation. EBITDA margin is expected to see an expansion Y-o-Y on the back of better products in the US market and higher sales contribution from Non-pen-non-ceph APIs.MTM losses on USD loans is possible which could be to the tune of Rs 1,300-1,500 Mn. PAT estimates indicated are not accounting for MTM losses as we treat the same as non-recurring. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
